SCHEMBL896038

SCHEMBL896038

O=C(O)C1CCN(c2ccccn2)CC1C(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.51
DPP8 Q6V1X1 1/20 0.51
DPP9 Q86TI2 1/20 0.51
DPP7 Q9UHL4 1/20 0.51
GPR119 Q8TDV5 1/20 0.46
GRM1 Q13255 4/20 0.45
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GRIN2B Q13224 1/20 0.43
RIPK1 Q13546 1/20 0.43
KDM4E B2RXH2 5/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
RECQL P46063 1/20 0.42
ADRB2 P07550 1/20 0.42
GAA P10253 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5954905 0.83 GPR119 (0.45) DPP4DPP8DPP9DPP7GPR119
SCHEMBL2572102 0.82 GRM1 (0.46) DPP4DPP8DPP9DPP7GPR119
SCHEMBL1440410 0.79 GPR119 (0.47) DPP4DPP8DPP9DPP7GPR119
SCHEMBL30919992 0.78 NOTUM (0.62) DPP4DPP8DPP9DPP7GRM1
SCHEMBL16695414 0.78 NOTUM (0.62) DPP4DPP8DPP9DPP7GRM1
SCHEMBL17234450 0.78 NOTUM (0.62) DPP4DPP8DPP9DPP7GRM1
SCHEMBL17234453 0.78 NOTUM (0.62) DPP4DPP8DPP9DPP7GRM1
SCHEMBL30919963 0.78 NOTUM (0.62) DPP4DPP8DPP9DPP7GRM1
Trifluoroacetic Acid SCHEMBL4749328 0.78 DPP4 (0.60) DPP4DPP8DPP9DPP7GPR119
SCHEMBL31549832 0.76 MAP4K4 (0.49) DPP4DPP8DPP9DPP7GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560978-B1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS INC (US) 2019-01-30 EP disclosed
US-20180251479-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2018-09-06 US disclosed
US-9994594-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2018-06-12 US disclosed
US-20170183362-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2017-06-29 US disclosed
US-9040703-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2015-05-26 US disclosed
US-20140371175-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2014-12-18 US disclosed
EP-2560978-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS Mars, Incorporated (US) 2013-02-27 EP disclosed
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2012-04-05 US disclosed
WO-2011133653-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251479-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 DPP4 603/4885DPP8 699/4885DPP9 45/4885
US-20170183362-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 DPP4 603/4885DPP8 699/4885DPP9 45/4885
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 DPP4 603/4885DPP8 699/4885DPP9 45/4885
US-20140371175-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 DPP4 603/4885DPP8 699/4885DPP9 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.